Daewoong Pharmaceutical (KOSE:A069620) - Stock Price, News & Analysis

A069620 Stock Overview

Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally.

A069620 fundamental analysis
Snowflake Score
Valuation	6/6
Future Growth	0/6
Past Performance	5/6
Financial Health	5/6
Dividends	1/6

Rewards

Trading at 62% below our estimate of its fair value

Earnings grew by 188.2% over the past year

Trading at good value compared to peers and industry

Analysts in good agreement that stock price will rise by 43.2%

Risk Analysis

Earnings are forecast to decline by an average of 3.4% per year for the next 3 years

Shareholders have been diluted in the past year

Daewoong Pharmaceutical Co., Ltd Competitors

Chong Kun Dang Pharmaceutical

KOSE:A185750

₩1.3t

Caregen

KOSDAQ:A214370

₩985.1b

Daewoong

KOSE:A003090

₩711.5b

DongKook Pharmaceutical

KOSDAQ:A086450

₩691.5b

Price History & Performance

Summary of all time highs, changes and price drops for Daewoong Pharmaceutical
Historical stock prices
Current Share Price	₩109,400.00
52 Week High	₩127,600.00
52 Week Low	₩88,300.00
Beta	0.90
1 Month Change	-11.49%
3 Month Change	-2.76%
1 Year Change	1.48%
3 Year Change	-24.81%
5 Year Change	-45.44%
Change since IPO	810.31%

Recent updates

Shareholder Returns

	A069620	KR Pharmaceuticals	KR Market
7D	-2.8%	-5.0%	-4.3%
1Y	1.5%	-1.4%	-1.0%

Return vs Industry: A069620 exceeded the KR Pharmaceuticals industry which returned -1.4% over the past year.

Return vs Market: A069620 exceeded the KR Market which returned -1% over the past year.

Price Volatility

Is A069620's price volatile compared to industry and market?
A069620 volatility
A069620 Average Weekly Movement	4.5%
Pharmaceuticals Industry Average Movement	4.6%
Market Average Movement	5.2%
10% most volatile stocks in KR Market	12.0%
10% least volatile stocks in KR Market	2.4%

Stable Share Price: A069620 has not had significant price volatility in the past 3 months.

Volatility Over Time: A069620's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1945	1,715	Seongsoo Park	www.daewoong.com

Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices.

Daewoong Pharmaceutical Co., Ltd Fundamentals Summary

How do Daewoong Pharmaceutical's earnings and revenue compare to its market cap?
A069620 fundamental statistics
Market cap	₩1.24t
Earnings (TTM)	₩121.74b
Revenue (TTM)	₩1.38t

10.3x

P/E Ratio

0.9x

P/S Ratio

Is A069620 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A069620 income statement (TTM)
Revenue	₩1.38t
Cost of Revenue	₩688.22b
Gross Profit	₩687.11b
Other Expenses	₩565.37b
Earnings	₩121.74b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	10.58k
Gross Margin	49.96%
Net Profit Margin	8.85%
Debt/Equity Ratio	47.9%

How did A069620 perform over the long term?

See historical performance and comparison

Dividends

0.5%

Current Dividend Yield

15%

Payout Ratio

A069620 Stock Overview

Rewards

Risk Analysis

Daewoong Pharmaceutical Co., Ltd Competitors

KOSE:A185750

₩1.3t

KOSDAQ:A214370

₩985.1b

KOSE:A003090

₩711.5b

KOSDAQ:A086450

₩691.5b

Price History & Performance

Recent News & Updates

New major risk - Revenue and earnings growth

Upcoming dividend of ₩600 per share at 0.5% yield

Daewoong Pharmaceutical Announces Successful 'Extra Strength' Results of US Phase 2 Clinical Trial for High-Dose Administration of Nabota

Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative GLP-1 Obesity Treatment with Advanced Microneedle Technology for Sustained Weekly Efficacy

Daewoong Therapeutics Gets Mfds Nod for Phase 1 Ind for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema

Price target decreased by 7.5% to ₩171,083

Recent updates

New major risk - Revenue and earnings growth

Upcoming dividend of ₩600 per share at 0.5% yield

Daewoong Pharmaceutical Announces Successful 'Extra Strength' Results of US Phase 2 Clinical Trial for High-Dose Administration of Nabota

Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative GLP-1 Obesity Treatment with Advanced Microneedle Technology for Sustained Weekly Efficacy

Daewoong Therapeutics Gets Mfds Nod for Phase 1 Ind for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema

Price target decreased by 7.5% to ₩171,083

Daewoong Pharmaceutical Obtains Approval for SGLT2i + Metformin Combination Drug Envlomet

New minor risk - Shareholder dilution

Avacta Group Plc (AIM:AVCT) acquired Unknown minority stake in AffyXell Therapeutics Co., Ltd. from Daewoong pharmaceutical Co.,Ltd (KOSE:A069620).

Daewoong Pharmaceutical Presents New Clinical Data of Fexuprazan at Digestive Disease Week 2023

Full year 2022 earnings released: EPS: ₩3,816 (vs ₩2,227 in FY 2021)

Now 20% undervalued after recent price drop

Price target decreased by 7.4% to ₩205,714

Investor sentiment deteriorates as stock falls 18%

Daewoong Pharmaceutical Begins the First Administration of Bersiporocin

Daewoong Pharmaceutical Co.,Ltd Submits NDA for Its Global New Drug Fexuclue in 11 Countries, Only 1 Year After Approval in Korea

Consensus forecasts updated

Upcoming dividend of ₩600 per share

Daewoong Pharmaceutical Announces Success in Developing New Antidiabetic Medication

Now 20% undervalued after recent price drop

Less than half of directors are independent

Daewoong Pharmaceutical Announces Phase 3 Clinical Trial Results of New Diabetes Treatment Enavogliflozin

Investor sentiment improved over the past week

Price target increased to ₩235,714

Daewoong Pharmaceutical Announces US FDA Clearance of IND Application for DWP213388, First-In-Class Irreversible Oral Dual Acting Inhibitor for Autoimmune Diseases

Price target increased to ₩235,000

Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug

Investor sentiment improved over the past week

Less than half of directors are independent

Daewoong Pharmaceutical Submits NDA for its Global New Drug Fexuclue Tablets to the Philippines

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Daewoong pharmaceutical Co.,Ltd Announces Successful Phase 3 Topline Results for New Antidiabetic Drug's Triple Combination Therapy

Daewoong Pharmaceutical Released Positive Phase 3 Topline Results for New Antidiabetic Drug

Upcoming dividend of ₩600 per share

Price target increased to ₩199,000

Daewoong Pharmaceutical Publishes Results of First Clinical Study of SGLT-2 Inhibitor 'Enavogliflozin' for Canine Diabetes

Daewoong Pharmaceutical of South Korea Announces PRS-Inhibitor for Idiopathic Pulmonary Fibrosis Shows Promising Result in Early Stage Clinical Test

First quarter 2021 earnings released: ₩2,139 loss per share (vs ₩65.00 profit in 1Q 2020)

Price target increased to ₩147,143

Evolus, Inc. and Daewoong Pharmaceuticals Co., Ltd. Enter into Settlement Agreement

Full year 2020 earnings released: EPS ₩1,196 (vs ₩2,132 in FY 2019)

Daewoong pharmaceutical Co.,Ltd., Annual General Meeting, Mar 26, 2021

New 90-day low: ₩121,000

Price target raised to ₩126,625

New 90-day high: ₩119,000

Third quarter 2020 earnings released: EPS ₩223

Price target lowered to ₩110,000

New 90-day low: ₩91,900

Daewoong Pharmaceutical Announces Korea's First-Ever SGLT2 Inhibitor for Diabetes Treatment

Price target lowered to ₩123,214